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Abstract (Word Count 250) 
Objective: To investigate the added prognostic value of admission measurements of brain 
natriuretic peptides (BNP) and troponins in patients with acute heart failure. 
Background: Plasma concentrations of BNP and troponin are often measured for diagnostic 
purposes when patients are admitted with heart failure. Their prognostic value when measured 
soon after admission is uncertain.   
Methods: Multivariable prognostic models for death or any worsening heart failure (WHF) by 
30 days; 30-day death or re-hospitalization for WHF; and 90-day mortality were constructed 
using baseline data from the Value of Endothelin Receptor Inhibition with Tezosentan in Acute 
heart failure Studies (VERITAS) including BNP and troponin-I. 
Results: Of 1347 patients, the median (IQR) value of BNP was 422 (156-945) pg/mL and 855 
(63%) had measurable troponin-I. By 30 days, 432 patients had died or experienced WHF. 
Clinical variables had only moderate predictive performance that was not substantially improved 
by BNP or troponin-I (c-indices 0.6528 and 0.6595). By 30 days, 150 patients died or were re-
hospitalized for WHF. The c-index using clinical variables (0.6855) was not improved by adding 
biomarkers. By 90 days, 135 patients had died. The c-index for mortality was somewhat better 
than for composite outcomes (0.7394) but improved little with biomarkers (0.7461). 
Conclusion: Routine clinical data recorded at the time of admission on patients with acute heart 
failure is poor at predicting recurrent admissions but somewhat better at predicting mortality. 
BNP or troponin measured at admission did not improve predictions; measurement closer to 
discharge, or of other novel biomarkers, might perform differently.  
 
Key words:  acute heart failure; prognosis; biomarkers; statistical models 
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Abbreviations and Acronyms 
BNP= b-type natriuretic peptide 
IDI= integrated discrimination index 
IQR= interquartile range 
LLOQ= lower limit of quantification 
MR-proANP= midregional pro-atrial natriuretic peptide 
NRI= net reclassification index 
NT-proBNP= amino-terminal pro-BNP 
VAS= visual analogue score 
VERITAS= Value of Endothelin Receptor Inhibition with Tezosentan in Acute Heart Failure 
Studies 
WHF= worsening heart failure 
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Introduction  
The prognosis of patients admitted to hospital with acute heart failure remains generally but not 
uniformly poor 1;2. Many patients will die or be re-admitted within 30-days but most will not. 
Stratifying risk could improve the planning and delivery of care. Identifying patients at high, 
short-term risk of readmission or death might reasonably lead to a delay in discharge or intensive 
post-discharge surveillance, either conventionally or with new remote monitoring technologies, 
provided such strategies can be shown to alter prognosis 3. However, prediction has to be fairly 
accurate to make risk stratification of this already high-risk population worthwhile. If too many 
cases are missed (false-negative cases) then clinicians would have no confidence in the strategy. 
If prediction includes too many false-positive cases then this might prolong hospital stay 
unnecessarily. If this was not accompanied by an increase in bed capacity, healthcare systems 
would not cope. 
 
Predictive models have been developed using data from patients with acute heart failure enrolled 
in surveys, registries, and clinical trials that provide insights into which characteristics are 
associated with an adverse outcome 4. Although these analyses have identified several predictors 
of outcome, they also show that existing predictive models are not very accurate, especially for 
re-admissions. Such models are of limited clinical use for managing individual patients or for 
service redesign. Bio-markers might improve prediction but whether they add prognostic value  
to standard routine clinical variables for patients with acute heart failure has seldom been 
reported 2;5-13. Accordingly, we took the opportunity to investigate the value of adding brain 
natriuretic peptide and troponins to conventional prognostic markers in a large multi-centre study 
of acute heart failure. 
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Methods 
The goal was to create parsimonious multivariable prognostic models for three outcomes: (1) the 
composite of death, WHF during the hospital stay, or re-hospitalization for WHF through 30 
days; (2) death or re-hospitalization for WHF through 30 days; and (3) death through 90 days. 
Readily available data gathered at baseline in the Value of Endothelin Receptor Inhibition with 
Tezosentan in Acute Heart Failure Studies (VERITAS) were used to create a basic predictive 
model14. The additional value of bio-markers, including B-type natriuretic peptides (BNP) and 
troponins, was then investigated. 
 
Patients. Patients enrolled in VERITAS within 24 hours of hospital presentation with WHF 
sufficient to cause breathlessness at rest or on minimal exertion were included in this analysis. 
The patient’s report of dyspnoea had to be supported by a respiratory rate of at least 24 breaths 
per minute as objective support of respiratory distress. The investigator’s clinical diagnosis of 
heart failure had to be supported by at least two of the following four criteria: (1) an elevated 
concentration of BNP or amino-terminal pro-BNP (NT-proBNP), (2) pulmonary oedema on 
physical examination, (3) radiological evidence of pulmonary congestion or oedema, or (4) left 
ventricular systolic dysfunction (left ventricular ejection fraction [LVEF] <40% or wall motion 
index <1.2) and also had to have received intravenous diuretics. Plasma concentrations of 
natriuretic peptides were rarely available at the time of inclusion. Most patients were included 
based on criteria two and three. Exclusion criteria included cardiogenic shock, 
electrocardiographic ST segment elevation myocardial infarction, ongoing ischemia or 
administration of a thrombolytic agent, a systolic blood pressure ≤100 mg Hg in patients not 
receiving a vasodilator or ≤120mm Hg in those receiving a vasodilator, haemoglobin 
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concentration ≤10 g/dL, serum creatinine concentration ≥2.5 mg/dL [to convert to μmol/L, 
multiply by 88.4]. Patients were randomized to receive intravenous tezosentan, an endothelin 
antagonist, or placebo. This did not influence any of the above outcomes and is not considered 
further in this analysis. 
 
Thirty-two predictors were considered (Supplementary Table S1), based on data available in 
VERITAS and on clinical judgement informed by the results of previous analyses from other 
studies of acute heart failure. To this were added two biomarkers: BNP and troponins that were 
measured from plasma samples obtained just prior to study drug initiation and stored at -20oC 
locally and shipped to a core laboratory where analyses were done 15. As described previously, 
(14) plasma concentrations of BNP and troponin I were measured using commercially-available 
ELISA kits: Peninsula Laboratories, San Carlos, USA for BNP; Labmaster, Turku, Finland for 
troponin I.  Troponin T was measured using an electrochemiluminescence immunoassay (Roche, 
Germany).  The lower limit of quantification (LLOQ) reported by the laboratory (BioProof AG, 
Munich, Germany) was 0.041 ng/mL for BNP, 0.01 ng/mL for troponin T and as not applicable 
(all results > 0 reported) for troponin I.  Because troponin I and T were highly correlated (r=0.87, 
p<0.0001) and a higher proportion of troponin T values were missing, troponin I was used for 
this analysis.  Non-detectable values were set to 0.5 times the LLOQ for BNP and to 0.5 times 
the minimum reported value for troponin I prior to log transformation.  
 
Statistical Analysis. Data are expressed as percentages for categorical data and as median and 
inter-quartile range for continuous data. The linearity of association between each continuously 
distributed predictor variables and each of the outcomes was assessed using restricted cubic 
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splines with 4 ‘knots’ with a test of the significance of the non-linear terms 16.  Where the 
association was non-linear, a readily-interpreted transformation was chosen through examination 
of plots of the predicted log hazard ratio against the value of the predictor and changes in 
Akaike’s Information Criterion.  If little information was lost, the same transformation was used 
to model each outcome.  A summary of the model forms chosen for each continuous predictor is 
shown in Supplementary Table S1. 
 
We used multiple imputation 17 with a method that assumes multivariate normality (SAS PROC 
MI) to handle missing values.  The imputation model included all covariates under consideration 
for the multivariable models.  The ranges of imputed values were restricted to the ranges of the 
observed values. Ten imputation datasets were used.  Parameter estimates were averaged across 
these datasets using Rubin’s algorithm 18 (SAS PROC MIANALYZE). 
 
We constructed two full models (one with and one without biomarker data) for each of the three 
outcomes that included all of the variables listed in Supplementary Table S1.   Backwards 
selection in each of the imputed datasets was then used to reduce the number of predictors, with 
the criterion for retention set at P<0.10.  Predictors that were significant in the majority of the 
imputed datasets (>5) were kept in each of the final models.   
 
The prediction ability of the resulting models was evaluated by computing differences in c-
statistics (c-indices) between models with and without the addition of biomarkers. Because 
multiple imputation was used with 10 imputations, the c-indices were calculated for each 
imputation dataset using Harrell’s method 19 and then averaged using Rubin’s algorithm in 
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PROC MIANALYZE. For each endpoint, c-indices and their difference are presented as bias-
corrected estimates with corresponding 95% confidence intervals based on 200 bootstrap 
samples of the imputed data sets.  
 
Results 
Of 1448 patients enrolled in the VERITAS studies and eligible for analysis, 101 (7.0%) were 
excluded because they were enrolled more than 24 hours from admission, leaving 1347 patients 
for this analysis. No patient was lost to follow-up. Natriuretic peptides were rarely measured by 
investigators and contributed to inclusion criteria in only 287 patients (20%). For this analysis, 
BNP and troponins were assayed retrospectively on stored plasma. The median age of patients 
was 72 (IQR 63-79) years and 41% were women. Most patients were Caucasian (87%) and had a 
pre-existing diagnosis of heart failure (73%). The prevalences of COPD (19%), diabetes (48%), 
renal dysfunction (37%) and atrial fibrillation (27%) were substantial. The median heart rate was 
82 (71-95) beats per minute and respiratory rate was 26 (24-28) breaths per minute. Median 
systolic blood pressure was 127 (115-144) mmHg. Left ventricular ejection fraction was reported 
only in 779 patients (54%) from measurements taken up to 12 months prior to admission and was 
therefore not considered in the model. At the time of randomization, 632 (47%) patients were 
receiving β-blockers, 711 (53%) ACE inhibitors, and 135 (10%) angiotensin II receptor. 
 
Values for BNP were generally elevated, with a median value of 422 pg/mL, although 74 (5%) 
patients had values below the assay’s LLOQ (41 pg/mL) (Figure 1a). Plasma troponin-I was 
measurable in 855 (63%) patients with a distribution that was highly skewed to the right (Figure 
1b). By 30 days, 432 patients had reached the composite outcome of death, in-hospital WHF by 
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day 7 or had been readmitted for WHF, and 150 had died or been re-hospitalized for WHF. By 
90 days, 135 patients had died. The impact of biomarkers on the consistency with which 
predictor variables were included in models for each outcome of interest is shown in 
Supplementary Table S1. 
 
Predictors of the composite outcome of death, WHF or readmission for WHF at 30 days in 
univariable analysis are shown in Table 1. Excluding biomarker data, the multivariable model 
included age, heart rate, respiratory rate, systolic blood pressure, history of COPD, history of 
diabetes, history congestive heart failure (CHF), history of renal impairment, dyspnea severity by 
visual analogue score (dyspnoea VAS) at baseline, albumin, BUN, haemoglobin, and sodium. 
The resulting c-index (0.6528) suggested only moderate predictive performance. BNP did not 
add to the model and troponin-I added little information, increasing the c-index only to 0.6595 
without significant differences in c-indices between models.  
 
By 30 days, 150 patients had died or been re-hospitalized for WHF. Age, heart rate, systolic 
blood pressure, history of CHF, dyspnea VAS at baseline, albumin, BUN, haemoglobin, and 
sodium were independent predictors of this outcome (Table 2). The final model resulted in a c-
statistic of 0.6855 which was not significantly improved by either biomarker.  Ninety-seven 
patients were rehospitalized for WHF within 30 days.  The risk of WHF hospitalization, given 
that the patient had not died, was associated with similar baseline characteristics but, again, 
neither troponin I nor BNP was predictive of this outcome. 
 
 
By 90 days, 135 patients had died. Biomarkers showed a much stronger relationship to mortality 
than to composite outcomes on univariable analysis (Table 3). Excluding biomarkers, the 
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multivariable model identified age, heart rate, systolic blood pressure, history of COPD, history 
of vascular disease, dyspnoea VAS at baseline, white blood cell count (WBC), albumin, BUN, 
and sodium as significant predictors of mortality with an overall c-index of 0.7394. BNP did not 
provide further prognostic information. The addition of troponin provided a small improvement 
in the c-index to 0.7461 and displaced WBC count from the model. The difference in c-indices 
between the two models was not statistically significant. 
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Discussion 
This and other models that attempt to predict 30-day morbidity and mortality amongst patients 
with acute heart failure based on standard clinical, biochemistry and haematology measurements 
have met with limited success. Typically, they report a c-index of about 0.65 which is only 
slightly better than the play of chance (0.5). Although the results may be highly statistically 
significant, this reflects the large number of patients studied rather than the predictive accuracy 
of the models. This lack of prognostic accuracy renders such models of little practical clinical 
use. We had hoped that measurement of biomarkers such as BNP and troponin would add 
substantially to the predictive power of clinical models but they did not, at least when measured 
shortly after admission. Biomarkers might not be able to improve prediction but could still 
simplify it, by replacing a large number of variables with just a few, which might be perceived as 
an advantage. However, this was not the case in the current analysis. 
 
Natriuretic peptides have predicted adverse outcomes in other studies and settings. Indeed, in 
out-patients with chronic heart failure, NT-proBNP is often the single strongest predictor of a 
variety of relevant outcomes including hospitalisation for WHF and death 20;21. Some studies of 
acute heart failure have found that natriuretic peptides provide incremental prognostic 
information to clinical models but others have not 2;5;22;23. This might depend not only on the 
specific natriuretic peptide measured but also on study size, the type of population included, the 
timing of the measurement of biomarkers, what other variables are in the model, the outcome of 
interest and the statistical analyses employed.  
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Large studies provide high statistical power and may demonstrate strong statistical associations 
that, however, may not be relevant to clinical practice. Demonstrating a statistical association 
should only be considered a first step, subsequent to which techniques such as classification and 
regression tree (CART), net reclassification index (NRI) and integrated discrimination index 
(IDI) should be applied to determine practical value. Superficial analyses even on very large 
data-sets can be seductively deceptive. For instance, in 87,842  patients with acute heart failure 
in the Acute Decompensated Heart Failure National Registry (ADHERE), a positive test for 
troponin (about 6% of patients) predicted in-hospital mortality but more than 80% of deaths 
occurred amongst patients who were troponin negative 24;25. 
 
Many studies report on the prognostic value of natriuretic peptides in patients presenting with 
acute breathlessness, many of whom do not have heart failure 9;10;26-29. In this setting, a 
biomarker that identifies patients with a disease that carries a poor prognosis is likely to predict 
outcome. However, the biomarker may perform less well when the analysis is confined to 
patients in whom the diagnosis of heart failure is already known 9;12.  
 
Serial measurements of natriuretic peptides suggest that values nearer discharge may be more 
closely associated with prognosis than those close to admission 23;30. Conceptually, natriuretic 
peptides might be considered cardiac stress markers although, because they are cleared by the 
kidney, renal dysfunction is also a major determinant of their plasma concentration. BNP is 
therefore, to some extent, a measure of renal function and will complete with other variables 
associated with renal function in multivariable models. If all other measures of renal function are 
removed from the model, then BNP would predict outcome but it would not be clinically 
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sensible to take such an approach. At the time of admission, plasma concentrations of natriuretic 
peptides might be a useful measure of cardiac stress. Plasma concentrations will generally fall 
with successful treatment although whether measurements treatment should be used to guide 
therapy is controversial 31. The final plasma concentration will reflect the residual stress in the 
system after implementation of effective treatment and could be considered a method of auditing 
the success of treatment 32. A patient who initially has a plasma BNP concentration that is only 
modestly elevated but rises during admission may have a worse outcome than a patient who 
starts with a high level that falls in response to treatment. Measurement of natriuretic peptides on 
admission may help with diagnosis 9;27;28 but even though their plasma concentrations are 
statistically related to in-hospital mortality 24, this provides no practical prognostic information 
for individual patient care.  However, pre-discharge measurements of biomarkers might be a 
guide to longer term outcomes 23;30. 
 
The specific marker measured and the outcome of interest may be important. For instance, the 
Biomarkers in Acute Heart Failure (BACH) trial showed that MR-proANP measured in the 
emergency room in 1,641 patients with suspected heart failure (diagnosis confirmed in 35%) 
predicted mortality at 7, 30 and 90 days and appeared superior in this respect to NT-proBNP 
with BNP trailing a poor third 33. On the other hand, for the composite of death or recurrent 
emergency consultation, BNP measured at the initial visit performed somewhat better than the 
other two natriuretic peptides. Other markers, such as pro-adrenomedullin 5;33 and copeptin 34 
might be better at predicting short-term outcome, although this may not be specific for heart 
failure related events. High-sensitivity assays for troponin have been introduced since this trial 
was completed that have the ability to detect and quantify plasma concentrations of troponin in 
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almost all patients. It is possible that such an assay could detect patients with very low troponin 
levels who might have a good prognosis. This could increase the prognostic value of troponin 
measured at admission.   
 
The significance of an elevated troponin may be somewhat different to that of an elevated BNP. 
Increases in troponin predominantly reflect cardiac myocyte damage with leakage of troponin 
across the cell membrane, reflecting cell damage and death. Myocardial infarction is often silent 
and silent infarcts may be more common in patients with heart failure because of damage to 
cardiac sensory nerves 35. Some elevations in troponin at the time of admission for heart failure 
are likely to reflect recent coronary events but others may reflect global myocardial stress and 
accelerated myocyte apoptosis 11;36;37. Because troponin may reflect the amount of cardiac 
damage leading to, or indeed caused by, the episode of acute heart failure, measurement at the 
time of admission might be expected to predict outcome, which it did to a modest extent in our 
analysis. Increases in troponin after admission may also confer an adverse prognosis 38. Our data 
are consistent with other reports showing statistical associations between troponin and mortality. 
However, it is not clear that this translates into a practical value.  
 
This and other analyses are consistent in showing that prognostic models are better at predicting 
death rather than morbidity. This may perhaps be because death is driven more by the biological 
processes measured in these models. Morbidity may be more influenced by factors such as 
patient education, social support, frailty, the relationship with healthcare staff, economic factors 
and local organization of health services 39. In order to develop useful predictive models for 
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hospital readmission it may be necessary to include many variables that are not usually collected 
by cardiologists in clinical trials or surveys. 
 
This analysis suggests that BNP and troponin measured at admission provide little or no extra 
information to variables collected in routine clinical practice. However, just because a marker is 
not independently related to prognosis does not mean that it is not a potential therapeutic target 
or a surrogate marker of improved outcome. Preventing an increase in troponin or ensuring that 
BNP falls with treatment might both improve outcomes 22 as suggested by the recent Relaxin in 
Acute Heart Failure (RELAX-AHF) study 40. There are many roles for biomarkers other than 
predicting outcome. Indeed, their potential to change management decisions is of much greater 
importance. If the term ‘biomarker’ is extended to heart rate and rhythm, blood pressure, 
potassium and renal function, then biomarkers are already used routinely to guide contemporary 
medical management of heart failure 41. However, controversy persists over the value of newer 
plasma biomarkers such as natriuretic peptides and troponin for guiding treatment of heart failure 
31;42.  
 
There are many limitations to our study. This was a clinical trial population. By protocol design, 
both low and very high risk patients were excluded. Many patients will have declined to 
participate and it is also likely that investigators decided not to include some patients even 
though they fulfilled the entry criteria. Accordingly, this is a selected group of patients. It is 
possible that the prognostic models would be more accurate in clinical practice that does not 
exclude patients at either extreme of risk, although it is in patients of intermediate risk where the 
assistance of tests may be most required 43. Many other variables might have been collected. 
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Intuitively, models developed using discharge rather than admission data might be better able to 
predict post-discharge outcome. Surprisingly, this does not seem to be the case for routine 
clinical information, with discharge data adding little to that collected at admission 2;44. However, 
this may not be the case for biomarkers 23;45. Conversely, an earlier measure of BNP might have 
better reflected the patient’s state at the time of admission and provided greater prognostic 
information. Although the biomarker measures must have been taken within 24 hours of 
admission for AHF, some measures may have been taken after administration of intravenous 
diuretics which may have affected them. Thus, the possible prognostic value of measures taken 
early in an AHF episode cannot be entirely dismissed. There were too few in-hospital deaths (53 
in our analysis population) to investigate prediction of this outcome.  
 
In conclusion, for patients with acute heart failure, conventional clinical assessments made 
shortly after admission are poor at identifying death or readmission by 30 days but somewhat 
better at predicting all-cause mortality by 90 days. Measurement of BNP and troponins at 
admission do not substantially improve prediction of any of these specified outcomes. 
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Figure legend 
Figure 1.  Distribution of baseline values for BNP (pg/mL, panel A), Troponin I (ng/ml, panel 
B). 
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Table 1.  Predictors of 30-day death, worsening heart failure, or rehospitalization for WHF 
 
Predictor*  
HR for a 
change of  
Univariable models  
Multivariable model 
without biomarkers  
Multivariable model 
with biomarkers  
HR 
95% 
CI 
P-
value 
HR 
95% 
CI 
P-
value 
HR 
95% 
CI 
P-
value 
Age, y (cubic)† 79 vs. 63 1.30 
(1.10, 
1.54) 
0.2504 1.27 
(1.06, 
1.52) 
0.0283 1.21 
(1.01, 
1.44) 
0.0946 
BMI, kg/m2 5 0.93 
(0.86, 
1.01) 
0.0958       
Heart rate, bpm 5 1.02 
(0.99, 
1.04) 
0.1805 1.03 
(1.00, 
1.06) 
0.0573  
  
Respiratory rate, 
≤24/min† 
5 0.75 
(0.55, 
1.03) 
0.0005 
0.76 
(0.55, 
1.06) 
0.0011 
0.74 
(0.53, 
1.03) 
0.0002 
Respiratory rate, 
>24/min† 
5 1.26 
(1.12, 
1.41) 
1.26 
(1.11, 
1.42) 
1.29 
(1.14, 
1.45) 
Systolic BP, mmHg 10 0.94 
(0.90, 
0.99) 
0.0109 0.95 
(0.91, 
1.00) 
0.0345 0.95 
(0.90, 
0.99) 
0.0214 
Hx of COPD Yes/No 1.37 
(1.10, 
1.71) 
0.0057 1.27 
(1.02, 
1.60) 
0.0354 1.29 
(1.03, 
1.62) 
0.0259 
Hx of DM Yes/No 1.35 
(1.11, 
1.63) 
0.0022 1.31 
(1.07, 
1.60) 
0.0084 1.30 
(1.06, 
1.59) 
0.0115 
Hx of IHD, PVD, or 
stroke 
Yes/No 1.28 
(1.04, 
1.59) 
0.0224       
Hx of Valve Disease Yes/No 1.44 
(1.15, 
1.82) 
0.0019       
Hx of CHF Yes/No 1.40 
(1.11, 
1.77) 
0.0041 1.22 
(0.96, 
1.55) 
0.0965 1.22 
(0.96, 
1.55) 
0.1002 
Hx of renal 
impairment 
Yes/No 1.67 
(1.38, 
2.02) 
<.0001 1.30 
(1.04, 
1.62) 
0.0229 1.26 
(1.01, 
1.58) 
0.0388 
dyspnea VAS, mm 
(cubic)† 
79 vs. 50 0.91 
(0.75, 
1.10) 
0.0745 0.89 
(0.73, 
1.09) 
0.0662 0.88 
(0.72, 
1.08) 
0.0736 
Time from admission 
to randomization, h 
1 0.99 
(0.98, 
1.01) 
0.2959    0.99 
(0.97, 
1.00) 
0.0721 
ECG QRS interval, 
ms 
10 1.03 
(1.00, 
1.06) 
0.0268       
Albumin, g/L 5 0.82 
(0.75, 
0.90) 
<.0001 0.86 
(0.78, 
0.95) 
0.0042 0.85 
(0.77, 
0.94) 
0.0025 
Log2 BUN, mmol/L Doubling 1.56 
(1.38, 
1.76) 
<.0001 1.26 
(1.08, 
1.46) 
0.0026 1.25 
(1.07, 
1.45) 
0.0043 
Creatinine, umol/L 10 1.07 
(1.05, 
1.10) 
<.0001       
Hemoglobin, g/dL 
(cubic)† 
14.62 vs. 
11.89 
0.68 
(0.56, 
0.82) 
<.0001 0.80 
(0.65, 
0.99) 
0.0080 0.80 
(0.65, 
0.99) 
0.0063 
Sodium, mmol/L  3 0.85 
(0.79, 
0.90) 
<.0001 0.89 
(0.83, 
0.95) 
0.0005 0.89 
(0.83, 
0.95) 
0.0006 
Log2 BNP, ng/ml Doubling 1.06 
(1.01, 
1.11) 
0.0274 
   
   
Log2 TnI, ng/ml Doubling 1.03 
(1.01, 
1.06) 
0.0038 
   
1.03 
(1.00, 
1.05) 
0.0276 
Bias-corrected c-index (95% CI) 0.6528 (0.6298, 0.6758) 0.6595 (0.6367, 0.6823) 
Difference (95% CI) 0.0067 (-0.0014, 0.0149) 
* Variables that are not shown were not significantly related to this outcome on uni- or multi-
variable analyses. †Non-linear association with outcome.  
BMI= body mass index; BP= blood pressure; CHF= chronic heart failure; CI= confidence 
interval; COPD= chronic obstructive pulmonary disease; DM= diabetes mellitus; ECG= 
electrocardiogram; HR= hazard ratio; IHD= ischemic heart disease; PVD= peripheral vascular 
disease; TnI= Troponin-I; VAS= visual analogue score.     
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Table 2. Predictors of Death or re-hospitalization for worsening heart failure by 30 days 
 
Predictor* 
HR for a 
change 
of 
Univariable models 
Multivariable model 
without biomarkers 
Multivariable model 
with biomarkers 
HR 
95% 
CI 
P-value HR 
95% 
CI 
P-value HR 
95% 
CI 
P-value 
Age, y 10 1.20 
(1.04, 
1.39) 
0.0104 1.25 
(1.08, 
1.44) 
0.0024 1.25 
(1.08, 
1.44) 
0.0024 
BMI, kg/m2 5 0.88 
(0.76, 
1.01) 
0.0739       
Heart rate, bpm 5 1.03 
(0.99, 
1.08) 
0.1278 1.05 
(1.00, 
1.10) 
0.0328 1.05 
(1.00, 
1.10) 
0.0328 
Systolic BP, 
mmHg 
10 0.89 
(0.82, 
0.96) 
0.0026 0.92 
(0.85, 
0.99) 
0.0355 0.92 
(0.85, 
0.99) 
0.0355 
Hx of Valve 
Disease 
Yes/No 1.54 
(1.05, 
2.25) 
0.0279       
Hx of CHF Yes/No 2.19 
(1.39, 
3.45) 
0.0007 2.13 
(1.34, 
3.37) 
0.0014 2.13 
(1.34, 
3.37) 
0.0014 
Hx of renal 
impairment 
Yes/No 1.68 
(1.22, 
2.32) 
0.0015       
Hx of smoking Yes/No 0.41 
(0.17, 
0.99) 
0.0485       
Baseline 
dyspnea VAS, 
mm 
10 1.08 
(1.00, 
1.16) 
0.0411 1.08 
(1.00, 
1.16) 
0.0456 1.08 
(1.00, 
1.16) 
0.0456 
ECG QRS 
interval, ms 
10 1.05 
(1.01, 
1.09) 
0.0282       
Albumin, g/L 5 0.78 
(0.65, 
0.93) 
0.0074 0.83 
(0.68, 
1.01) 
0.0678 0.83 
(0.68, 
1.01) 
0.0678 
Log2 BUN, 
mmol/L 
Doubling 1.85 
(1.52, 
2.25) 
<.0001 1.65 
(1.33, 
2.06) 
<.0001 1.65 
(1.33, 
2.06) 
<.0001 
Creatinine, 
umol/L 
10 1.10 
(1.06, 
1.13) 
<.0001       
Hemoglobin, 
g/dL 
(quadratic)† 
14.62 vs. 
11.89 
0.73 
(0.58, 
0.90) 
0.0011 0.92 
(0.72, 
1.18) 
0.0678 0.92 
(0.72, 
1.18) 
0.0678 
Sodium, 
mmol/L 
3 0.79 
(0.71, 
0.88) 
<.0001 0.83 
(0.75, 
0.93) 
0.0014 0.83 
(0.75, 
0.93) 
0.0014 
Log2 BNP, 
ng/ml 
Doubling 1.06 
(0.98, 
1.16) 
0.1627       
Log2 TnI, ng/ml Doubling 1.03 
(0.99, 
1.07) 
0.1893       
Bias-corrected c-index (95% CI) 0.6855 (0.6408, 0.7302) 0.6855 (0.6408, 0.7302) 
*Variables (other than biomarkers) that are not shown were not significantly related to this 
outcome on uni- or multi-variable analyses. †Non-linear association with outcome.  
BMI= body mass index; BP= blood pressure; CHF= chronic heart failure; CI= confidence 
interval; ECG= electrocardiogram; HR= hazard ratio; TnI= Troponin-I; VAS= visual analogue 
score.    
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Table 3.  Predictors of Mortality at 90 days 
 
Predictor* 
HR for a 
change 
of 
Univariable models 
Multivariable model 
without biomarkers 
Multivariable model 
with biomarkers 
HR 
95% 
CI 
P-value HR 
95% 
CI 
P-value HR 
95% 
CI 
P-value 
Age, y 10 1.53 
(1.29, 
1.80) 
<.0001 1.46 
(1.23, 
1.72) 
<.0001 1.42 
(1.20, 
1.69) 
<.0001 
White race Yes/No 1.94 
(1.02, 
3.70) 
0.0433       
BMI, ≤30 kg/m2 
† ‡ 5 
0.60 
 
(0.46, 
0.78) 
0.0001 
      
BMI, >30 kg/m2 
† ‡ 
5 1.01 
(0.77, 
1.32) 
      
Heart rate, bpm 5 1.05 
(1.00, 
1.10) 
0.0530 1.05 
(1.00, 
1.10) 
0.0313 1.05 
(1.00, 
1.10) 
0.0353 
Respiratory 
rate, /min 
5 1.17 
(0.98, 
1.40) 
0.0849       
Systolic BP, 
mmHg 
10 0.87 
(0.80, 
0.95) 
0.0014 0.89 
(0.82, 
0.97) 
0.0086 0.89 
(0.81, 
0.97) 
0.0072 
Hx of COPD Yes/No 1.81 
(1.25, 
2.62) 
0.0016 1.58 
(1.08, 
2.30) 
0.0179 1.59 
(1.09, 
2.32) 
0.0159 
Hx of IHD, 
PVD, or stroke 
Yes/No 2.04 
(1.31, 
3.17) 
0.0016 1.75 
(1.11, 
2.76) 
0.0169 1.60 
(1.01, 
2.54) 
0.0451 
Hx of Valve 
Disease 
Yes/No 1.61 
(1.08, 
2.39) 
0.0190       
Hx of renal 
impairment 
Yes/No 1.81 
(1.29, 
2.54) 
0.0006       
Dyspnea VAS, 
mm 
10 1.08 
(1.00, 
1.17) 
0.0427 1.08 
(1.00, 
1.17) 
0.0495 1.08 
(1.00, 
1.17) 
0.0570 
WBC, 109/L 5 1.38 
(1.15, 
1.67) 
0.0006 1.23 
(1.01, 
1.49) 
0.0375    
Albumin, g/L 5 0.74 
(0.62, 
0.88) 
0.0006 0.75 
(0.62, 
0.90) 
0.0029 0.76 
(0.63, 
0.91) 
0.0042 
Log2 BUN, 
mmol/L 
Doubling 1.79 
(1.46, 
2.21) 
<.0001 1.52 
(1.21, 
1.90) 
0.0003 1.52 
(1.20, 
1.91) 
0.0004 
Creatinine, 
umol/L 
10 1.09 
(1.05, 
1.14) 
<.0001       
Hemoglobin, 
g/dL 
1 0.89 
(0.81, 
0.98) 
0.0145 
   
   
Sodium, 
mmol/L 
(quadratic) † 
141 vs. 
136.4 
0.84 
(0.70, 
1.00) 
<.0001 0.88 
(0.74, 
1.05) 
0.0074 0.84 
(0.71, 
0.99) 
0.0019 
Log2 BNP, 
ng/ml 
Doubling 1.15 
(1.05, 
1.27) 
0.0027 
      
Log2 TnI, ng/ml Doubling 1.11 
(1.06, 
1.16) 
<.0001 
   
1.07 
(1.02, 
1.12) 
0.0023 
Bias-corrected c-index (95% CI) 0.7394 (0.6988, 0.7800) 0.7461 (0.7072, 0.7851) 
Difference (95% CI) 0.0067 (-0.0085, 0.0218) 
* Variables that are not shown were not significantly related to this outcome on uni- or multi-
variable analyses †Non-linear association with outcome. ‡ risk falls as BMI rises towards 30. 
BMI= body mass index; BP= blood pressure; CI= confidence interval; COPD= chronic 
obstructive pulmonary disease; HR= hazard ratio; IHD= ischemic heart disease; PCI= 
percutaneous coronary interventions; PVD= peripheral vascular disease; TnI= Troponin-I; VAS= 
visual analogue score.    
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Figure 1. Distribution of baseline values for BNP (pg/mL, panel A), Troponin I (ng/ml, panel B). 
 
a) 
 
 
 
b)  
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Supplementary Table S1.  Candidate predictors 
 
Variable 
N (% 
missing) 
Prevalence (%) 
or  
Median & 
Quartiles 
Sel. Freq. 
wo/w 
Biomarke
rs M1† 
Sel. Freq. 
wo/w 
Biomarker
s M2‡ 
Sel. Freq. 
wo/w 
Biomarker
s M3§ 
Transformation 
Age, y 1347 
(0%) 
72 (63, 79) 10/8 10/10 10/10 Cubic polynomial 
for M1†. 
Men 797 
(0%) 
(59.2%) 0/0 0/0 0/0  
White Race 1167 
(0%) 
(86.6%) 0/0 0/0 0/0  
BMI, kg/m2 1274 
(5.4%) 
27.7 (24.6, 31.9) 0/0 0/0 3/4 Linear spline with 
one knot (nadir of 
risk) at 30 for 
M3§. 
Heart rate, bpm 1346 
(0.1%) 
82.0 (71.0, 94.5) 8/3 10/10 10/9  
Respiratory 
rate, /min 
1330 
(1.3%) 
26.0 (24.0, 28.0) 10/10 0/0 0/3 Linear spline with 
one knot (nadir of 
risk) at 24 for 
M1†. 
Systolic BP, 
mmHg \ 
1332 
(1.1%) 
127 (115, 144) 10/10 10/10 10/10  
Hx of COPD 260 
(0.1%) 
(19.3%) 10/10 0/0 10/10  
Hx of DM 642 
(0.1%) 
(47.7%) 10/10 0/0 0/0  
Hx of IHD, 
PVD, or stroke 
940 
(0.1%) 
(69.8%) 0/0 0/0 10/9  
Hx of Valve 
Disease 
220 
(0.1%) 
(16.3%) 1/0 0/0 0/0  
Hx of CHF 981 
(0.7%) 
(73.4%) 7/7 10/10 0/0  
Hx of 
hyperlipidemia 
472 
(0.1%) 
(35.1%) 0/0 0/0 0/0  
Hx of 
hypertension 
1067 
(0.1%) 
(79.3%) 0/0 0/0 0/0  
Hx of renal 
impairment 
500 
(0.9%) 
(37.5%) 10/10 0/0 0/0  
Hx of liver 
disease 
105 
(0.9%) 
(7.9%) 0/0 0/0 0/0  
AF at 
admission 
356 
(0.9%) 
(26.7%) 0/0 0/0 0/0  
Hx of smoking 102 
(0.1%) 
(7.6%) 0/0 0/0 0/0  
Hx of PCI or 
CABG 
473 
(0.1%) 
(35.1%) 0/0 0/0 0/0  
Baseline 
dyspnea VAS, 
mm 
1328 
(1.4%) 
66 (50, 79) 8/10 10/10 10/10 Cubic polynomial 
for M1†. 
Admission to 
randomization, 
h 
1347 
(0%) 
9.1 (4.6, 16.6) 4/7 0/0 0/0  
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Variable 
N (% 
missing) 
Prevalence (%) 
or  
Median & 
Quartiles 
Sel. Freq. 
wo/w 
Biomarke
rs M1† 
Sel. Freq. 
wo/w 
Biomarker
s M2‡ 
Sel. Freq. 
wo/w 
Biomarker
s M3§ 
Transformation 
ECG QRS 
interval, ms 
1338 
(0.7%) 
103 (84, 134) 0/0 0/0 0/0  
Sodium, 
mmol/L 
1329 
(1.3%) 
139.0 (136.4, 
141.0) 
10/10 10/10 10/10 Quadratic 
polynomial for 
M3§. 
BUN, mmol/L 1304 
(3.2%) 
8.2 (6.2, 11.3) 10/10 10/10 9/10 Log2-transform to 
reduce skewness. 
Creatinine, 
umol/L 
1344 
(0.2%) 
108.7 (88.4, 
139.7) 
0/0 0/0 1/0  
Albumin, g/L 1034 
(23.2%) 
38.0 (34.6, 41.5) 10/10 8/8 10/10  
ALT, U/L 1169 
(13.2%) 
18.6 (12.6, 29.4) 0/0 0/0 0/0 Log2-transform to 
reduce skewness. 
Hemoglobin, 
g/dL 
1346 
(0.1%) 
13.3 (11.9, 14.6) 10/10 10/10 0/0 Quadratic for M2‡ 
and cubic 
polynomial for 
M1†. 
WBC, 109/L 1339 
(0.6%) 
9.0 (7.2, 11.4) 0/0 0/0 10/0  
BNP, pg/ml 1255 
(6.8%) 
422 (156, 945) NR/0 NR/0 NR/0 Set zero to 0.5 x 
LLOQ for log2 
transform. 
Troponin-I, 
ng/ml 
1254 
(6.9%) 
0.03 (0.00, 0.13) NR/10 NR/0 NR/10 Non-detectable set 
to 0.5 x min for 
log2 transform. 
Troponin-T, 
ng/ml 
1223 
(9.2%) 
0.00 (0.00, 0.06)    Collinear with 
troponin-I. 
Sel. Freq. w/wo = selection frequency out of 10 imputation datasets with and without addition 
of biomarker data.  †M1= death, worsening heart failure or readmission for heart failure by Day 
30. ‡M2 = death or readmission for heart failure by Day 30. § M3 = all-cause mortality by Day 
90. \Systolic and Diastolic BP were highly collinear and latter was dropped from the model. 
AF= atrial fibrillation; BMI= body mass index; BP= blood pressure; CABG= coronary artery 
bypass surgery; CHF= chronic heart failure; COPD= chronic obstructive pulmonary disease; 
DM= diabetes mellitus; ECG= electrocardiogram; IHD= ischemic heart disease; LLOQ= lower 
limit of quantification; NR= not relevant; PCI= percutaneous coronary interventions; PVD= 
peripheral vascular disease. 
 
